Alkem Laboratories, a key player in the pharmaceutical sector, has announced the launch of a generic medication aimed at treating type-2 diabetes mellitus, chronic kidney disease, and chronic heart failure. This move sees Alkem introducing empagliflozin and its combinations in the Indian market under the brand name Empanorm, at prices significantly lower by 80% compared to innovator medications.
About the Author
